Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Radiprodil - Algernon Pharmaceuticals

Drug Profile

Radiprodil - Algernon Pharmaceuticals

Alternative Names: NP 121; RGH-896; UCB-3491

Latest Information Update: 22 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Gedeon Richter
  • Developer Algernon Pharmaceuticals; Forest Laboratories; Gedeon Richter; PRA Health Sciences; UCB
  • Class Non-opioid analgesics; Small molecules
  • Mechanism of Action NMDA receptor antagonists; NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis
  • Discontinued Epilepsy; Infantile spasms; Neuropathic pain; Pain; Parkinson's disease

Most Recent Events

  • 03 Jul 2019 Preclinical trials in Idiopathic pulmonary fibrosis in Canada before July 2019 (PO)
  • 07 Mar 2019 Discontinued - Phase-I for Epilepsy in Belgium (PO) before March 2019 (UCB Biopharma pipeline, March 2019)
  • 07 Mar 2019 Discontinued - Phase-I for Pain (In volunteers) in Netherlands (PO) before March 2019 (UCB Biopharma pipeline, March 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top